REPLIGEN CORP Derivative Liability, Current
REPLIGEN CORP (RGEN) had Derivative Liability, Current of $9.19 million as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2025-08-07
- 2025-06-30: Derivative Liability, Current $9.19M.
- 2025-03-31: Derivative Liability, Current $8.19M.
- 2024-12-31: Derivative Liability, Current $0.00.
| Period end | Derivative Liability, Current |
|---|---|
| 2025-06-30 | $9.19M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $8.19M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $0.00 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |